Cullinan Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+1.93%
vs ±23.3% implied · ×0.08
shaded = implied · ▲▼ = realized
Cullinan Therapeutics has 7 disclosed suppliers and 1 disclosed customer in SEC filings.
SentenceWe have a collaboration agreement (the "Adimab Collaboration Agreement"), with Adimab, LLC ("Adimab").
CGEM 10-Kaccession 0001193125-26-099362
SentenceChongqing Genrix Biopharmaceutical Co., Ltd. ("Genrix"), from which we licensed velinotamig, is enrolling a Phase 1 clinical trial in China in patients with autoimmune diseases, initially in patients with SLE, followed by planned future expansion into other indications, and initial clinical data will be shared in the fourth quarter of 2026.
CGEM 10-Kaccession 0001193125-26-099362
SentenceWe are party to an exclusive license agreement (the "DKFZ/Tübingen License Agreement") for CLN-049 through our CLN-049 development subsidiary, Cullinan Florentine Corp. ("Cullinan Florentine"), with Deutsches Krebsforschungszentrum ("DKFZ"), Eberhard Karls University of Tübingen, Faculty of Medicine ("University of Tübingen"), and Universitätsmedizin Gesellschaft für Forschung und Entwicklung mbH, Tübingen ("UFE").
CGEM 10-Kaccession 0001193125-26-099362
SentenceWe are party to an exclusive license agreement (the "DKFZ/Tübingen License Agreement") for CLN-049 through our CLN-049 development subsidiary, Cullinan Florentine Corp. ("Cullinan Florentine"), with Deutsches Krebsforschungszentrum ("DKFZ"), Eberhard Karls University of Tübingen, Faculty of Medicine ("University of Tübingen"), and Universitätsmedizin Gesellschaft für Forschung und Entwicklung mbH, Tübingen ("UFE").
CGEM 10-Kaccession 0001193125-26-099362
SentenceCLN-418 is a B7H4x4-1BB bispecific antibody that we licensed from Harbour BioMed US Inc. ("Harbour") and were previously evaluating in a Phase 1 clinical trial.
CGEM 10-Kaccession 0001193125-26-099362
SentenceWe had an exclusive patent license agreement (the "MIT License Agreement") for the technology underlying CLN-617 with MIT through our development subsidiary, Cullinan Amber Corp. ("Cullinan Amber").
CGEM 10-Kaccession 0001193125-26-099362
SentenceZipalertinib (CLN-081/TAS6417), on which we are collaborating with an affiliate of Taiho Pharmaceutical Co., Ltd. ("Taiho"), is an orally-available small-molecule, irreversible epidermal growth factor receptor ("EGFR") inhibitor that is designed to selectively target cells expressing EGFR exon 20 insertion mutations ("EGFR ex20ins") with relative sparing of cells expressing wild-type EGFR.
CGEM 10-Kaccession 0001193125-26-099362
SentencePursuant to a co-development agreement, we are collaborating with a Taiho affiliate to develop zipalertinib for the treatment of a genetically defined subset of patients with NSCLC, and Taiho will commercialize zipalertinib.
CGEM 10-Kaccession 0001193125-26-099362
Cullinan Therapeutics, Inc.
14.90
Largest filed tie
—
Expected move
No implied move.